Secondary Prevention of Venous Thrombo Embolism (VTE).
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The general aim of this study is to determine the comparative safety and efficacy of
dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR)
of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous
thromboembolism in patients who have been successfully treated with standard doses of an
approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous
Thrombo-embolism.